Literature DB >> 1001354

Studies on hydralazine. III. Bioavailability of hydralazine in man.

T Talseth.   

Abstract

The bioavailability of orally administered hydralazine was assessed in 4 healthy subjects after separate administration of a single oral or intravenous dose (0.3 mg-kg-1). Comparison of the areas under the serum concentration-time curves showed that 26-55% of the oral dose was available to the systemic circulation as unchanged drug. The 0-24 h excretion of the drug in urine was rapid: 11.4-14.1% of the dose after intravenous administration, and 2.0-3.6% after an oral dose. Acetylation of hydralazine leads to formation of 3-methyl-s-triazolo-3,4, aphthalazine (MTP) and a gas-liquid-chromatographic method for its measurement in urine was developed. After oral and intravenous administration, 0.8-1.2% and 1.4-2.3% of the dose, respectively, were recovered within 24 hours from urine as MTP. After oral administration there was a relative increase in the amount of MTP in every subject, which indicates route-dependent metabolism. The lower bioavailability of oral hydralazine could be explained in terms of first-pass metabolism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1001354     DOI: 10.1007/bf00563075

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Identification of two new metabolites of hydralazine from human urine.

Authors:  S B Zak; T G Gilleran; J Karliner; G Lukas
Journal:  J Med Chem       Date:  1974-03       Impact factor: 7.446

3.  Disposition of hydralazine in man and a specific method for its determination in biological fluids.

Authors:  S B Zak; M F Bartlett; W E Wagner; T G Gilleran; G Lukas
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

4.  Relation of hydralazine plasma concentration to dosage and hypotensive action.

Authors:  R Zacest; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

5.  The metabolism of 1-hydrazinophthalazine: the correct structure of the pseudo-"N-acetyl-1-hydrazinophthalazine".

Authors:  S Edwards; F H Marquardt
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1969-01

6.  Metabolism and disposition of hydralazine-14C in man and dog.

Authors:  J M Lesser; Z H Israili; D C Davis; P G Dayton
Journal:  Drug Metab Dispos       Date:  1974 Jul-Aug       Impact factor: 3.922

7.  3-Hydroxymethyl-s-triazolo[3,4-a]phthalazine, a novel urinary hydralazine metabolite in man.

Authors:  H Zimmer; R Glaser; J Kokosa; D A Garteiz; E V Hess; A Litwin
Journal:  J Med Chem       Date:  1975-10       Impact factor: 7.446

8.  The determination of hydralazine in plasma by gas-liquid chromatography.

Authors:  D B Jack; S Brechbüher; P H Degen; P Zbinden; W Riess
Journal:  J Chromatogr       Date:  1975-12-10

9.  Identification of 3-methyl-s-triazolo(3,4-alphathalazine, a human hydralazine metabolite, by gas chromatography-mass spectrometry.

Authors:  H Zimmer; J Kokosa; D A Garteiz
Journal:  Arzneimittelforschung       Date:  1973-08

10.  Multiple N-acetyltransferases and drug metabolism. Tissue distribution, characterization and significance of mammalian N-acetyltransferase.

Authors:  D J Hearse; W W Weber
Journal:  Biochem J       Date:  1973-03       Impact factor: 3.857

  10 in total
  13 in total

Review 1.  Acrolein-mediated injury in nervous system trauma and diseases.

Authors:  Riyi Shi; Todd Rickett; Wenjing Sun
Journal:  Mol Nutr Food Res       Date:  2011-08-08       Impact factor: 5.914

Review 2.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

3.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 4.  Drug kinetics and hepatic blood flow.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

6.  Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

Authors:  D D Shen; J P Hosler; R L Schroder; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

7.  Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.

Authors:  V Facchini; J A Timbrell
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

8.  Drug metabolism by the gastrointestinal mucosa.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

9.  Autoradiographic study of the distribution of [3H]- and [14C]-hydrallazine in the rat.

Authors:  J R Baker; G R Bullock; I H Williamson
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

10.  Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.

Authors:  M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.